NATCO Pharma Canada arm invests over Rs 67 crore in biotech company eGenesis

eGenesis is a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure. The eGenesis Genome Engineering and Production (EGEN) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant.

eGenesis is advancing development programs for kidney transplant, acute liver failure, and heart transplant. “We are excited to get involved with eGenesis, Inc. with respect to their pioneering work in xenotransplantation. We agree with the vision of eGenesis that xenotransplantation technology has the potential to end the global transplant shortage and transforming the treatment of organ failure by eliminating waitlist mortality,” said Rajeev Nannapaneni, Vice Chairman and CEO of NATCO Pharma Limited.

“We are thrilled to welcome NATCO as an investor. Their support will be used in advancing our research and bringing our innovative therapies to market,” said Mike Curtis, CEO of eGenesis, Inc.

Also Read:Lung cancer drug: Natco Pharma submits ANDA for generic version of Novartis Tabrecta

NATCO Pharma Limited is a vertically integrated pharmaceutical company headquartered in Hyderabad, India.

eGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, USA, focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.

Also Read:Migraine drug: Natco Pharma submits application for generic version of Rimegepant Sulfate tablet with USFDA